glp-1 weight loss drug news today 2025 Market Size, Share GLP-1 Drugs Revolutionize Weight Loss

Unfortunately, utilization of Saxenda has significantly declined in recent years and now represents less than 1% of the anti-obesity medication market

The content is solely the responsibility of the authors and does not necessarily represent the official views of any of the funders

On the other hand, Mounjaro delivers even greater metabolic benefits, with studies showing up to 20% weight loss, making it a formidable contender for both diabetes and obesity treatment

The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs

While these changes require commitment, they lay the foundation for lasting success

2 Treatment for type 2 diabetes is initiated based on (glycated hemoglobin) HbA1C levels, treatment goals, and cardiovascular, renal, as well as hypoglycemia risk